John O'Brien (he/him)’s Post

We are delighted to share that we have been successful in securing SBRI Healthcare funding for our Phase I feasibility study exploring the utility of #BioEP in paediatric epilepsy diagnosis. This is supported by the Accelerated Access Collaborative and in partnership with the Health Innovation Network. In collaboration with clinical partner Professor Rohit Shankar MBE Shankar we will review paediatric epilepsy biomarkers and incorporate these into our #BioEP diagnostic decision support tool. Our ambition for Phase II is to validate the updated tool in a retrospective trial proving the evidence base for clinicians to use #BioEP to support faster and more accurate diagnosis of epilepsy in children. As part of our commitment to #sustainability, we’re working with Innovative Energy Consultants to measure, reduce and offset our research's carbon footprint #NetZero. John Terry Co-Founder & Managing Director Neuronostics "We are thrilled to be part of this drive to improve health outcomes in children. Expanding the capabilities of BioEP to enable its use to support a diagnosis of epilepsy in children is a key part of our future strategy." Verena Stocker, Interim Director of Innovation, Research, Life Sciences and Strategy, NHS England and Chief Executive Office, Accelerated Access Collaborative “The SBRI Healthcare awards help the NHS to develop new technologies and solutions to address some of the biggest healthcare challenges facing society. We have selected these innovations because they have the potential to make a big difference to improving the health and wellbeing of children and young people. By supporting the most promising innovations, the NHS will continue to evolve, helping to meet more patients’ needs and encouraging more innovators to come forward with innovative ideas that benefit all.” https://lnkd.in/eDEUyRKi

The Victorian Government is backing Victoria, #Australia’s homegrown #medicalresearch sector, with the seventh round of applications of the Victorian Medical Research Acceleration Fund (VMRAF) now open – helping to deliver support to early-stage research, the fast-tracking projects from #research to real-world impact, while putting Victoria at the forefront of global medical research innovation. Grants of up to $100,000 will support early-stage innovative research projects that demonstrate potential for practical application at a later stage, while grants of up to $500,000 will assist researchers in translating their products and practices into clinical or health care settings.   Since 2017, the VMRAF has invested more than $20.4 million to advance Victoria’s medical research sector, supporting 113 research projects. Applications close on 1 December 2023. More: https://lnkd.in/gYp9w2mY #ThinkMelbourne #Melbourne

A Letter from the ASCAT Program Chair: Insights, Innovations, and Collaborative Action Await To My Fellow ASCAT Conference Attendees, Over the last decade, we have witnessed unprecedented advances in research as well as the development of long-awaited new treatments for individuals affected by Sickle Cell Disease and Thalassaemia. This remarkable progress, as well as the impressive pipeline of potential new therapies, will be highlighted during ASCAT 2024. We will hear the lived experiences and perspectives of those directly affected by Haemoglobinopathies and the advocacy and legislative actions being taken to address remaining concerns. We will learn from experts across the globe about a variety of topics including pre-conception counseling, newborn screening, organ damage, access to care, and algorithms to choose the best course of treatment for each individual patient. As we developed this year’s program, we wanted to be certain to balance our celebration of the marked progress in treatment options with the reality that this progress has not been equally meaningful for all who are affected. Our conference theme embodies this sentiment: “Achieving Equitable Progress: A Call for Collaborative Action in a World of Growing Disparities.” As such, ASCAT 2024 will have didactic sessions, panel discussions, and ample networking time to understand and enhance global efforts to narrow the evolving disparities in diagnostic, care, and treatment access. We especially encourage young and promising researchers, doctors, and students to join us. Your fresh perspectives and innovative ideas are crucial to the continued advancement of our field. This is a unique opportunity to learn, share, and network with leading experts and peers dedicated to closing the Haemoglobinopathy equity gap. I look forward to welcoming you to ASCAT 2024! Biree Andemariam, M.D. #ASCAT2024 www.ascatconferences.com

Returning home from the wonderful annual meeting of the European Charcot Foundation (ECF) in the enchanting Baveno, Italy - a moment to reflect on this exciting journey: 🧠 Starting the journey, with the face-2-face kick-off meeting of the CLAIMS initiative. It was a true pleasure having our partners together and establishing the next steps to the “companion diagnostic platform”. This platform aims to provide data-driven #personalised clinical decision support by addressing the new insights in disease worsening due to both relapses and disease progression independent of relapses (#PIRA), powered by #deeplearning technology. A special thanks to the incredible medical experts, including Giancarlo Comi, Dana Horáková, patrick vermersch, Friedemann Paul, Hans-Peter Prof. Hartung, whose insights illuminated the potential of the platform to transform the lives of people with MS - and as always, to all our medical, scientific and pharma partners to make this initiative possible. 🧠 Next-up, a truly inspiring update on the Global PROMS Initiative, featuring international experts, patients and industry representatives. Discussions focussed on the complexities of patient reported outcomes in terms of clinical validation and functional domain interdependencies, but also highlighted the need of this information for clinical decision making and the critical role of #digital #eHealth tools. The PROMS eHealth Tools Catalogue hosted by the MS Data Alliance provides a great overview, also featuring #icompanion - standing out as the most downloaded medical device - empowering individuals with MS to contribute valuable outcomes data. 🧠 I also truly enjoyed the participation in the “Multi-Stakeholder Initiatives” annual meeting, fostering collaboration in the MS world to ultimately improve the lives of MS patients together. Great to witness these initiatives joining forces with ECF, including EMSP - European Multiple Sclerosis Platform, MS International Federation (MSIF), MSBrain Health, Mystery Solved Project, MS in the 21st Century, European Research Project for Excellence in MS, ParadigMS Foundation, Global PROMS Initiative, AISM, and the MS Data Alliance 🧠 Finally, the ECF meeting provided a fantastic scientific overview that really showed the importance of “Promoting and measuring recovery in MS”. The high standing sessions provided me novel insights on demyelination in terms of the influences of genetics and comorbidities, and the potential of monitoring via PROs and MRI. In the current landscape, where discussions on disease progression take center stage, we must not forget that actively promoting remyelination is a valid strategy to slow down progression and perhaps, even promote recovery. A big thank you to the European Charcot Foundation for the impeccable organization of this inspiring event. As #icometrix, we are proud to stand as partners, committed to advancing the frontiers of #AI #neuroimaging in the pursuit of better #MScare.

The Sean M. Healey and AMG Center: A Pioneering Force in ALS Research and Care. The Sean M. Healey and AMG Center at Massachusetts General Hospital has emerged as a beacon of hope for ALS patients and researchers worldwide. Founded by renowned neurologist Merit Cudkowicz, the center has made significant strides in accelerating the development of new therapies for this devastating neurodegenerative disease. A key innovation spearheaded by the Healey Center is the ALS Platform Trial, a groundbreaking approach that simultaneously evaluates multiple experimental drugs in a single study. This innovative model has garnered praise from patients, drugmakers, and experts alike for its potential to expedite the drug development process and bring much-needed treatments to ALS patients sooner. The Healey Center's impact extends beyond its clinical trials. It has also played a pivotal role in fostering collaboration among researchers and drug developers, breaking down silos and accelerating progress in the field. Additionally, the center has championed patient advocacy, ensuring that the voices of those living with ALS are heard and considered in the research process. As the Healey Center continues its groundbreaking work, it stands as a testament to the power of innovation, collaboration, and patient-centered care in the fight against ALS. Its contributions have not only brought hope to patients but have also reshaped the landscape of ALS research and care. #ALS #ALSResearch #SeanMHealeyCenter #ALSPlatformTrial #ALSCare #ALSPatientAdvocacy #HopeForALS #BreakingGroundInALSResearch https://lnkd.in/etFn5gY8

At this year's CX Symposium, the Vascular Access Masterclass featured a Great Debate titled “EndoAVFs are a failed experiment", during which Tobias Steinke, Robert Shahverdyan, MD 🇦🇲🇩🇪, Shannon Dean Thomas and Monnie Wasse, MD, MPH presented cases both in support of and against the motion. To learn more about the debate, the arguments that were made, and how the audience responded, follow the link below to read our full article!

Protocol paper for The Perfect-CR Implementation Study, a cluster-randomized effectiveness-implementation hybrid trial, is out! It´s exciting to venture into the field of implementation science - an important but at the same time often neglected side of CVD research. We have so much knowledge on what is best for our patients (stop smoking, eat healthy, exercise, lower lipids and blood pressure...) but still we fail to help them. Hopefully, our study will add some knowledge on how to become better. With Maria Bäck, Therese Scott Duncan, Björn Ekman, Emil Hagström, Maria Hägglund, Matthias Lidin, Bertil Lindahl, Halldóra Michelsen, and Mona Schlyter. Thanks to #hjärtlungfonden, FORTE, Medicinska fakulteten, Lunds universitet and Region Skåne for making this journey possible <3

View new session of the ‘Best Practice Exchange in Clinical Case Scenarios’ to listen to experts in UC discussing the latest evidence supporting the optimal utilization of sequential treatments. https://lnkd.in/ecjStWAe

How to come down from the #SCOPE2024 high? (Ch 2/2)   What I did to land myself softly back in reality: I I went to visit one of our investigator sites, right there in Orlando.   Not a big site network, not a key academic centre - just one of the hundreds of sites taking care of our trials every day. Strongly embedded in the local communities and linked to HCP’s around them. It was the most refreshing reality check I could think of.    In the round of introductions I mentioned SCOPE2024 as my reason for travelling to Orlando, how exciting the many solutions and technological innovations are that will make the work for the site so much easier and the patient engagement better. As I noticed the investigator's and study coordinator’s eyes glaze over, I realised: wait, why am I talking? I want to LISTEN to what they can tell me!    Let me share some of this with you: they know many of the companies from the SCOPE exhibition hall. And they told me about the distance between what is shown in the demos and the booths on one hand, and the way things work in a site in Orlando on the other hand.The harsh reality is that what we in the conference room see as a breakthrough technology is not what makes a difference for this site in Orlando – nor for others I recently visited.    How about we all start to listen what sites tell us, when we ask them what would increase their success?    We would hear their ask to have study information materials in relevant languages ready *before* the community event, not two weeks after. The ask on behalf of caregivers of study participants for a compensation for the time *they* have to take off work to accompany their parent with Alzheimer’s Disease to the study visit.    We would hear which central IRB, which central lab, which recruitment solution, which patient reimbursement provider, which e-signature solution they prefer, and why.    We would hear how challenging it can be for the research site to contract with ‘external’ specialists for certain protocol assessments and how the availability of for example MRI, PETscan, ophthalmology exam is fully engaged by patient care, leaving clinical trial needs last in line.    I dare to believe that we, sponsors and CROs and all companies contributing to clinical operations, can make a difference if we really LISTEN to sites, and act on what we HEAR.    Who is with me on this journey? I look forward to hearing your experiences and perspectives.    Reach out to me to discuss how our Syneos Health teams can partner with you in making a difference - for investigators and sites around the world. And please share below what you would like me to HEAR about making life easy for clinical investigator sites. #clinicaltrials #clinicalresearch #clinicaloperations #sitecentricity #clinicalinnovation #scopesummit Syneos Health Syneos Health Clinical Solutions Yenilady Estevez

We are thrilled to share that Avegen, in collaboration with King's College London, is one of the eight companies selected by the MHRA £10 million pilot for the Innovative Devices Access Pathway (IDAP)! IDAP aims to accelerate the development of innovative medical devices that meet unmet clinical needs in the NHS. It aligns with the government's long-term plan for faster access to groundbreaking technologies for the NHS and its patients. Currently, in the pilot stage, IDAP is supported by the Medicines and Healthcare Products Regulatory Agency (MHRA), @The National Institute for Health and Care Excellence (NICE), NHS England, Health Technology Wales, and Scottish Health Technology Group, and it aims to expedite the testing of new technologies on a large scale. This selection demonstrates the potential breakthrough status of Avegen's Multiple Sclerosis (MS) fatigue app developed in partnership with KCL that delivers personalised care to patients living with MS. Many with MS endure debilitating fatigue resistant to rest. While medications are common, evidence shows balance exercises, cognitive behaviour therapy, and targeted physical activity are more effective for MS fatigue. Unfortunately, limited NHS capacity restricts access to these options. Our smartphone app delivers personalised MS-fatigue management, guided by health experts, enhancing accessibility to NICE-recommended programs for improved quality of life. As a part of the IDAP support initiative, we will receive expert guidance about the product roadmap, regulatory requirements and the opportunity to pilot the solution in the NHS. Congratulations to all of the selected companies. We are excited about the potential impact on patients' lives and the future of healthcare innovation! #HealthcareRevolution #FutureOfHealth #AvegenInnovates https://lnkd.in/edwGcvQ4 Neha Gupta